Novartis AG ADR (NVS)

91.46
+0.20(+0.22%)
After Hours
91.59
+0.13(+0.14%)
- Real-time Data
  • Volume:
    2,160,004
  • Day's Range:
    90.59 - 91.47
  • 52 wk Range:
    79.09 - 95.17

NVS Overview

Prev. Close
91.26
Day's Range
90.59-91.47
Revenue
53B
Open
91.02
52 wk Range
79.09-95.17
EPS
10.73
Volume
2,160,004
Market Cap
197.65B
Dividend (Yield)
2.1614
(2.36%)
Average Vol. (3m)
2,589,779
P/E Ratio
8.52
Beta
0.53
1-Year Change
3.37%
Shares Outstanding
2,171,940,280
Next Earnings Date
Jul 19, 2022
What is your sentiment on Novartis ADR?
or
Market is currently closed. Voting is open during market hours.

Novartis AG ADR News

  • Novartis Tops Q1 EPS by 2c
    • ByInvesting.com-

    Novartis (NYSE:NVS) reported Q1 EPS of $1.46, $0.02 better than the analyst estimate of $1.44. Revenue for the quarter came in at $12.53 billion versus the consensus estimate of...

  • Novartis ADR Earnings Beat, Revenue Misses In Q1
    • ByInvesting.com-

    Investing.com - Novartis ADR reported on Tuesday first quarter earnings that beat analysts' forecasts and revenue that fell short of expectations. Novartis ADR announced earnings...

Novartis AG ADR Analysis

Novartis AG ADR Company Profile

Novartis AG ADR Company Profile

Employees
110000

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
  • https://seekingalpha.com/pr/18243773-sellas-life-sciences-reports-full-year-2020-financial-results-and-provides-business-update
    1
    • buy
      0
      • A
        0
        • just to know. I'm lost.this is the company that bought the medicines company?
          0
          • before investing in @novartis, read #teampia (twitter).
            0
            • sell 89 expecting 80 timeframe 5 days
              1
              • Long ENDOCYTE... I work in the field
                0
                • $NVS: Novartis AG Looking at All Options Including IPO for Alcon Unit.. This is HUGE catalyst for $NVS share holders!!!!!
                  0
                  • Buy this stock tomorrow as will be halted all day on Wednesday!
                    0
                    • I am willing to bet that FDA advisory committee WILL recommend their CTL019 drug!Post
                      0